Evidence map›Paper›PMID 36540524›Full record

ArticleCureus2022

A Case Report of Exfoliative Bullous Rash Following AstraZeneca Vaccine.

Usman Saleem, Elizabeth S Goh

Abstract readCase Reports
In one paragraph

Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Usman SaleemGeneral Internal Medicine, Hampshire Hospital Foundation Trust, Winchester, GBR.
Elizabeth S GohGeneral Internal Medicine, Hampshire Hospital Foundation Trust, Winchester, GBR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has affected globally; but thanks to vaccines, the effect has been countered with the help of a vaccination programme. We report a case of exfoliative bullous rash in a 69-year-old lady admitted to the acute medicine unit with complaints of rash post-AstraZeneca (AZ) vaccine administration. The rash initially started under her breast and had spread to other parts of the body without mucosal involvement. She was noted to have neutrophilia and raised inflammatory markers and subsequently commenced on antibiotics. Histology showed sub-epidermal blistering but negative immunofluorescence which excluded immune-bullous disease. A significant improvement was seen, and the presentation subsided after treatment with antibiotics and emollient therapy.

Indexed as

astra zeneca covid-19 vaccinecovid-19exfoliative bullous rashside effect post vaccinationvaccine related rash

Identifiers

PMID36540524
PMCPMC9755911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.